New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
16:05 EDTBIND, AMGNBIND Therapeutics, Amgen will not exercise development option
BIND Therapeutics (BIND) announce the completion of its collaborative research program with Amgen (AMGN) originally entered into in January 2013. Amgen and BIND have notified each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. “The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen. Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued,” said Scott Minick, Chief Executive Officer of BIND Therapeutics. “We remain focused on the continued development of our Accurin platform, including our proprietary drug candidate, BIND-014, and our collaborations with AstraZeneca and Pfizer, as well as our recently announced research collaboration with Roche. Furthermore, consistent with our previous guidance, we continue to expect that our cash, cash equivalents and short-term investments, and research development funding that we expect to receive under our existing collaborations, excluding any potential milestone payments, will fund our operating expenses and capital expenditure requirements through at least mid-2015.”
News For BIND;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
16:01 EDTAMGNAmgen submits Biologics License Application to FDA for ABP 501
Subscribe for More Information
November 24, 2015
05:42 EDTAMGNAmgen announces EU approval of Blincyto
Subscribe for More Information
November 23, 2015
14:10 EDTAMGNAmgen's PCSK9 inhibitor Repatha gets exclusive deal with CVS
Subscribe for More Information
November 22, 2015
15:03 EDTAMGNMerck reports multiple data sets from Keytruda combination studies
Subscribe for More Information
November 19, 2015
16:06 EDTAMGNAmgen's Kyprolis approved for multuple myeloma by European commission
Amgen announced the European Commission granted marketing authorization for Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The EC approved Kyprolis based on data from the pivotal Phase 3 ASPIRE trial. The study showed that patients treated with Kyprolis in combination with lenalidomide and dexamethasone had increased median time to progressive disease or death by 8.7 months compared to patients treated with lenalidomide and dexamethasone. Approval from the EC grants a centralized marketing authorization with unified labeling in the 28 countries that are members of the EU. Norway, Iceland and Liechtenstein, as members of the European Economic Area, will take corresponding decisions on the basis of the decision of the EC. Amgen plans to submit data from the Phase 3 ENDEAVOR trial for potential authorization of Kyprolis in combination with dexamethasone in the EU. This data also serves as the basis of the supplemental New Drug Application of Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma, which has been accepted for priority review by the FDA.
November 18, 2015
16:43 EDTBINDBIND Therapeutics gets $4M milestone payment from AstraZeneca
Subscribe for More Information
08:02 EDTBINDBIND says AstraZeneca initiates patient dosing in AZD2811 Phase 1 trial
Subscribe for More Information
November 16, 2015
16:05 EDTAMGNAmgen to present eight IMLYGIC abstracts
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use